B.Riley Financial analyst Mayank Mamtani reiterated a Hold rating on Novavax (NVAX – Research Report) today and set a price target of $15.00. The company’s shares opened today at $8.20.
Mamtani covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Agenus, and Gritstone Oncology. According to TipRanks, Mamtani has an average return of -15.8% and a 30.20% success rate on recommended stocks.
Currently, the analyst consensus on Novavax is a Hold with an average price target of $17.25.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $76.77 and a one-year low of $5.61. Currently, Novavax has an average volume of 5.78M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Read More on NVAX:
